

**SCRIP, the leading pharmaceutical magazine in the world Crowns Glenmark as the “Best Pharma Company in the World - SME” and the “Best Company in Emerging Markets” at the SCRIP Awards 2008 in London**

- SCRIP Awards recognises the best and brightest in the pharmaceutical and biotech industries worldwide
- Glenmark is the only Indian company to have received this prestigious recognition

**December 11, 2008:** The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 SCRIP Awards hosted by the leading UK broadcaster Peter Sissons on December 10<sup>th</sup>. At this award ceremony, which is one of the most prestigious recognitions for pharmaceutical organisations worldwide, **Glenmark was recognised as the Best Pharma Company in the World – SME” and the “Best Company in Emerging Markets”**. SCRIP is the leading pharmaceutical magazine in the world which organises this award ceremony where all the big names in the pharma world not only compete for this recognition but also attend this award ceremony.

In a press statement issued by SCRIP, it states “Glenmark crowned a busy year by winning the SCRIP Awards for Best Company in an Emerging Market and Pharma Company of the year for small and medium-sized enterprises. In his judging, Dr. Richard Barker said the Indian firm “scored well on almost all dimensions, showing dramatic growth in its generics business plus a promising early stage pipeline in some high potential areas for branded medicines”. Other judges agreed. **“Glenmark is a phenomenon!” said Dr. Viren Mehta**” The article further mentioned “While no company swept the board in 2008, Glenmark Pharmaceuticals and GlaxoSmithKline Biologicals were the night’s biggest winners, each garnering two awards”

**Commenting on this achievement, Mr. Glenn Saldanha, MD & CEO, Glenmark Pharmaceuticals limited who was present at the award ceremony mentioned** “This is a very big honour for our organisation. We are extremely glad that at this award ceremony which had all the biggest names in the pharma world attend and participate, Glenmark has triumphed. Most importantly, we are glad to showcase to the world that an Indian company can do pioneering work in the area of innovative research and consistently discover new chemical and biological entities for chronic diseases in novel therapeutic target areas”

For more information on the SCRIP Awards, please log on to [http://www.scripnews.com/top\\_news/2008-scrip-awards-celebrate-industrys-achievements-2197](http://www.scripnews.com/top_news/2008-scrip-awards-celebrate-industrys-achievements-2197)

#### **About Glenmark**

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Its shares are listed on India's two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). It employs over 5500 people across its global operations across 85 countries. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.] dermatology and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark's first Asthma/COPD molecule, Oglemilast was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. GRC 6211, molecule for pain and inflammatory disorders has been out-licensed to Eli Lilly & company. Glenmark's API and generics business interests span over the highly regulated markets of USA, Latin America and Europe, and are managed by its subsidiary Glenmark Generics Limited. For more information on GPL, log on to [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

#### ***For further information, please contact:***

Jason D'Souza / Medha Satam  
Glenmark Pharmaceuticals Limited  
Tel: [+91 22] 40189919 / 40189993  
Email : [media@glenmarkpharma.com](mailto:media@glenmarkpharma.com)